课题基金 / 基金详情

REGULATION OF INTRACELLULAR CALCIUM IN PARATHYROID CELLS

REGULATION OF INTRACELLULAR CALCIUM IN PARATHYROID CELLS
甲状旁腺细胞内钙的调节
批准号:
2391437
负责人:
DOLORES M. SHOBACK
金额:
$26.57万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-06-01 至 1999-03-31

项目摘要

项目成果

DOLORES M. SHOBACK的其他基金

相似基金

相关文献

中文摘要
翻译
PTH分泌受细胞外(EC)[Ca 2 +]的变化控制。 高EC Ca 2+抑制,低EC Ca 2+最大限度地刺激PTH释放。 EC [Ca 2 +]还通过影响PTH的前代谢来调节PTH的生物合成。 proPTH mRNA水平和PTH基因转录。后一种效应是 可能是至关重要的慢性适应血清钙的变化, vivo. Ca 2+被认为与最近发现的膜Ca 2+相互作用 该传感器与磷脂酶C激活、1,4,5-InsP 3形成 持续增加[Ca 2 +]i,并最终抑制PTH 分泌物甲状旁腺细胞内持续的钙反应 需要EC Ca 2+,我们推测,这是由于膜的开放 Ca 2+通道。关于药理学的信息很少, 生物化学或分子特性的Ca 2+内流途径, 副甲状腺细胞通过全细胞膜片钳技术,我们记录了Ca 2 + 电流是电压不敏感的,阳离子选择性的,被 La ~(3+)和Gd ~(3+)。 在微量荧光法研究中,Gd 3+显著降低 细胞内Ca 2+对高EC [Ca 2 +]的反应,强调了 Gd ~(3+)可阻断电流在介导Ca ~(2+)内流中的重要性后 进一步分析,Ca ~(2+)电流由2个分量组成。一 分量是电压不敏感电流,其电导取决于 EC [Ca 2 +]的变化。 这种电流被二氢吡啶阻断 Ca 2+通道拮抗剂和负调节蛋白激酶A。的 另一种电流成分是电压依赖性的,受蛋白质调节 激酶C本研究有4个目的:(1)探讨 [Ca 2 +]i持续升高介导PTH慢性抑制 分泌和生物合成,通过测量PTH释放和pre-proPTH mRNA 与选择性诱导瞬时 或短暂加持续增加[Ca 2 +]i;(2)定义 甲状旁腺细胞中钙通道的特性,并评估其 通过磷酸化和鸟苷酸调节;(3)评估 Ca ~(2+)电流对[Ca ~(2+)]i持续增加的贡献及其 在高EC Ca 2+诱导的PTH分泌/生物合成抑制中的作用, 使用通道激动剂和拮抗剂;和(4)从一种或多种细胞中分离cDNA, 甲状旁腺cDNA文库,其编码二氢吡啶敏感的Ca 2 + 通道,表达在非洲爪蟾卵母细胞,并确定是否这 通道可以耦合到Ca 2+传感器。甲状旁腺细胞的钙通道 可以作为一个关键机制,用于转换由 EC Ca 2+与Ca 2+传感器的相互作用。这些渠道可能 有助于长期适应钙缺乏状态或慢性 体内高钙条件。
英文摘要
PTH secretion is controlled by changes in the extracellular (EC) [Ca2+]. High EC Ca2+ inhibits, and low EC Ca2+ maximally stimulates PTH release. The EC [Ca2+] also modulates PTH biosynthesis through effects on pre- proPTH mRNA levels and PTH gene transcription. These latter effects are likely to be crucial in the chronic adaptation to changes in serum Ca2+ in vivo. Ca2+ is thought to interact with a recently identified membrane Ca2+ sensor which couples to phospholipase C activation, 1,4,5-InsP3 formation, sustained increases in [Ca2+]i, and eventually, to the inhibition of PTH secretion. Sustained intracellular Ca2+ responses in parathyroid cells require EC Ca2+ and, we hypothesize, result from the opening of membrane Ca2+ Channels. Little information is available on the pharmacologic, biochemical, or molecular properties of Ca2+ influx pathways in parathyroid cells. By whole-cell patch-clamping, we have recorded Ca2+ currents which are voltage-insensitive, cation-selective and blocked by La3+ and Gd3+. In microflurimetry studies, Gd3+ markedly reduces intracellular Ca2+ responses to high EC [Ca2+], underscoring the potential importance of Gd3+-blockable Currents in mediating Ca2+ influx. Upon further analysis, the Ca2+ currents are comprised of 2 components. One component is a voltage-insensitive current whose conductance is dependent on changes in the EC [Ca2+]. This current is blocked by dihydropyridine Ca2+ channel antagonists and negatively modulated by protein kinase A. The other current component is voltage-dependent and regulated by protein kinase C. The studies proposed have 4 aims: (1) to investigate the role of sustained increases in [Ca2+]i in mediating chronic suppression of PTH secretion and biosynthesis, by measuring PTH release and pre-proPTH mRNA levels in cells incubated with agents which selectively induce transient or transient plus sustained increases in [Ca2+]i; (2) to define the properties of Ca2+ channels in parathyroid cells and assess their regulation by phosphorylation and guanyl nucleotides; (3) to assess the contribution of Ca2+ currents to sustained increases in [Ca2+]i and their role in high EC Ca2+-induced suppression of PTH secretion/biosynthesis, using channel agonists and antagonists; and (4) to isolate a cDNA from a parathyroid cDNA library, which encodes a dihydropyridine-sensitive Ca2+ channel, as expressed in Xenopus oocytes, and to determine whether this channel can couple to the Ca2+ sensor. Ca2+ channels in parathyroid cells may serve as a key mechanism for transducing signals initiated by the interaction of EC Ca2+ with the Ca2+ sensor. These channels are likely to contribute to the longterm adaptation to Ca2+ deficiency states or chronic hypercalcemic conditions in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Combination Therapy for Osteoporosis in Men
Novel Combination Therapy for Osteoporosis in Men
Novel Combination Therapy for Osteoporosis in Men
Novel Combination Therapy for Osteoporosis in Men
海外基金